Beam Therapeutics reports positive BEACON Phase 1/2 results for risto-cel, meeting key efficacy and safety endpoints in severe sickle cell disease.
Written By: Sravani Pamanji, PharmD
Reviewed By: Pharmacally Editorial Team
Beam Therapeutics announced positive topline results on November 10, 2026, from BEACON, its Phase 1/2 trial evaluating ristoglogene autogetemcel (risto-cel, formerly BEAM-101) in patients with severe sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs). The investigational, one-time autologous cell therapy achieved the trial’s primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months, based on independently adjudicated results.
About the BEACON Trial
BEACON (NCT05456880) is an ongoing, open-label, single-arm, multicentre Phase 1/2 study evaluating risto-cel in patients with severe SCD. The primary efficacy endpoint is freedom from severe VOCs for at least 12 consecutive months (VF12), while secondary endpoints include freedom from inpatient hospitalisation for severe VOCs over the same period.
As of the October 20, 2026, data cutoff, 49 patients comprising 39 adults and 10 adolescents had received risto-cel. Of these, 31 had completed the required follow-up period for assessment of the VF12 endpoint.
How Risto-cel Works
Risto-cel is an investigational genetically modified cell therapy based on Beam’s base-editing technology. The treatment uses patients’ own CD34+ haematopoietic stem and progenitor cells (HSPCs), which are collected and base-edited in the promoter regions of the HBG1 and HBG2 genes.
These edits are designed to inhibit binding of the transcriptional repressor BCL11A to the HBG1/HBG2 promoters without disrupting BCL11A expression itself, thereby increasing fetal haemoglobin (HbF) production. Unlike sickle haemoglobin (HbS), HbF has non-sickling and anti-sickling properties that can counteract the effects of HbS.
Following myeloablative conditioning with busulfan, the genetically modified cells are returned to the patient via an autologous haematopoietic stem cell transplantation (HSCT) procedure. The therapeutic objective is to establish sustained HbF production and provide a durable clinical benefit from a single administration.
Efficacy: Primary and Secondary Endpoints Met
BEACON achieved its primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months, confirmed through independent adjudication. The study also met all secondary efficacy endpoints, including freedom from inpatient hospitalisation for severe VOCs over the same 12-month period.
Although these findings support the potential of risto-cel to reduce the burden of severe VOCs, Beam has not disclosed detailed response rates, the exact proportion of evaluable patients achieving VF12, or full statistical results in its topline announcement. Consequently, the magnitude of the treatment benefit cannot yet be independently assessed.
Safety: Prespecified Endpoints Met
The study met all primary safety endpoints at the prespecified interim analysis. As of the October 20, 2026, cutoff, safety findings remained consistent with previously reported BEACON data and the known, intended effects of plerixafor mobilisation and cell collection, busulfan-based myeloablative conditioning, autologous HSCT, and underlying SCD.
While these findings provide an encouraging initial safety assessment, longer follow-up remains necessary to characterise the treatment’s long-term safety profile, identify potential late-emerging adverse events, and confirm the durability of its therapeutic effects.
Regulatory Status
Beam expects to submit a Biologics License Application (BLA) for risto-cel to the US Food and Drug Administration (FDA) as early as the end of 2026. According to the company, the planned application could become the first BLA submission for a base-editing therapy.
Beam will also present results from an earlier BEACON data cutoff in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled for December 12–15, 2026, in New Orleans. Detailed pivotal results are planned for presentation at a medical meeting in 2027.
Clinical Interpretation
The BEACON topline findings represent a notable clinical milestone for base-editing approaches in SCD. Meeting all primary and secondary efficacy endpoints alongside prespecified primary safety goals supports continued development of risto-cel and the company’s planned regulatory filing.
However, the findings require cautious interpretation. BEACON is an open-label, single-arm study lacking a control group, and only 31 of the 49 treated patients had completed the required follow-up for primary endpoint assessment at the data cutoff. The absence of detailed response rates and statistical estimates also limits evaluation of the magnitude of benefit.
Additionally, the treatment pathway carries substantial clinical burdens and risks associated with stem cell collection, busulfan-based myeloablative conditioning, and autologous transplantation, which must be weighed against potential benefits. Interim safety data also do not yet establish long-term safety or multi-year durability.
Overall, BEACON strengthens the clinical case for risto-cel as a potential one-time therapy for severe SCD. Forthcoming detailed dataset presentations and FDA review will be critical in determining whether these outcomes translate into a favourable long-term benefit-risk profile supporting regulatory approval.
Reference
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease, Beam Therapeutics, 10 November 2026
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients with Severe Sickle Cell Disease (BEACON), ClinicalTrials.gov ID NCT05456880
About the Writer
Sravani Pamanji is a PharmD (LinkedIn) professional with experience in scientific writing, medical literature review, drug profile preparation, and clinical case documentation. She has contributed to scientific publication and presented at the 74th Indian Pharmaceutical Congress. Her training includes ICH GCP E6(R3), scientific research, and medication safety. She is passionate about evidence-based medical communication and accurate dissemination of clinical and pharmaceutical information.